Color Health links virtual oncology intake to NCI-designated cancer centers
Cancer care often breaks down before the first infusion ever reaches the chart. Records sit in separate systems, imaging arrives late, insurance questions stall scheduling, and patients who are already facing a new diagnosis lose precious time while the workup is assembled. Color Health is trying to shorten that gap by formalizing collaborations with 10 National Cancer Institute-designated cancer centers and routing patients through a more coordinated intake process.
The company’s model centers on a virtual, oncologist-led clinic that can prepare the clinical workup, review medical records, and complete authorizations tailored to each center’s requirements. When a patient is matched to a partner institution, Color coordinates directly with that team so the referral does not begin as a cold handoff. It is a logistical task, but in oncology, logistics and biology are inseparable: a faster diagnostic pathway can determine whether disease is found when it is still locally treatable or after it has already advanced.
Speed was the unifying theme in the discussions around the new arrangements. Caroline Savello, president of Color, framed the clinical goal in blunt terms: faster diagnosis and faster treatment initiation remain among the biggest determinants of cancer outcomes. That matters because the interval between suspicion and therapy is not just administrative downtime; it is the period in which tumor burden can rise, symptoms can worsen, and a patient’s ability to tolerate treatment may erode.
Coordination before the first oncology visit
The collaboration is built around work that often happens behind the scenes. Color and the participating centers are aligning on imaging, laboratory testing, records preparation, and custom intake workflows so that the patient can arrive at the right clinic with fewer missing pieces. First-appointment targets for most patients referred by Color Medical are set at seven days or fewer, and Color also verifies insurance coverage to keep referrals in network when possible.
When coverage is not straightforward, Color may work with payers or cancer centers on single-case agreements. In practical terms, this keeps a referral from collapsing over a reimbursement issue after the clinical decision has already been made. Patients who ultimately are not best served by a particular center can be rerouted, and issues that arise during care are escalated by Color clinicians to the collaborating institutions.
The participating centers span major academic cancer programs, including City of Hope-Los Angeles, Memorial Sloan Kettering, Moffitt Cancer Center, Mount Sinai, Stanford Medicine Cancer Center, UC Davis Comprehensive Cancer Center, and UCSF Helen Diller Family Comprehensive Cancer Center. These are NCI-designated cancer centers, meaning they have undergone rigorous evaluation for quality, safety, and access standards. In oncology, that designation carries weight because patients and clinicians alike are looking for institutions built to handle complex disease, rare tumor types, and the treatment sequencing problems that come with multidisciplinary care.
One sentence captures the core advantage here: the referral itself becomes part of the treatment plan.
Why intake speed changes the course of care
Cancer is not a single disease, and it does not behave like a single disease. Some patients need a confirmed diagnosis, others need a second opinion, and others need access to specialized therapies or clinical trials that are not available locally. A virtual intake system can reduce repetition, limit duplicate testing, and lower the risk that a patient is bounced between offices while the clock keeps running. In a disease where delays can force treatment changes later or increase the chance of emergency department visits and hospitalizations, the value of a streamlined path is easy to understand.
Color says its oncology model is designed around that reality. The company works with local providers to clinically manage patients through an oncologist-led care team, then extends support beyond the initial workup. Patients can receive nutrition support, mental health care, palliative care, and survivorship care through the same framework. That wider safety net matters because the burden of cancer is never limited to the primary tumor. Anxiety, poor intake, pain, treatment fatigue, and long-term functional decline often shape whether a plan can actually be carried out.
Karen Lu, M.D., physician in chief at Moffitt Cancer Center, described the model as patient-centered and said it blends technology with a human touch. Laurel Bray-Hanin, vice president at UCSF Helen Diller Family Comprehensive Cancer Center, described screening and diagnosis as deeply stressful moments and said the partnership connects Color’s coordination work with UCSF’s patient navigators so patients can quickly identify and schedule the next step. In both comments, the emphasis is on the same operational problem: patients do not need more complexity when a possible cancer diagnosis is already destabilizing enough.
Trial navigation, survivorship care, and employer demand
Color also plans to collaborate with the centers to identify potential clinical trial candidates, collect needed information, and support institution-led eligibility assessment and enrollment. That role can be especially important in oncology, where access to trials often depends on how quickly a patient can be screened and whether essential data are assembled in the correct format. A trial slot lost to paperwork is still a lost trial slot.
The company’s expansion also reflects demand from employers and health plans. Savello said Color expanded dramatically this year, including a partnership with Independence Blue Cross, and expects to serve millions more new lives in the coming year through employers. Those employers, she said, continue to focus heavily on oncology as health costs rise. The business case is familiar: cancer remains one of the largest drivers of healthcare spending and mortality, so even modest improvements in coordination can translate into fewer unnecessary tests, fewer delays, and fewer downstream complications.
Color launched its cancer-focused work in 2023 and says its patients have seen 66% faster diagnosis and a 77% increase in screening adherence. It also says it saves $62,000 per patient in treatment and closes more than three-quarters of costly care gaps. Those figures point to a model that is trying to influence both utilization and outcomes, though the operational question is whether those gains can be maintained as the network expands and the referrals become more complex.
The new collaborations suggest a broader shift in oncology toward distributed care with centralized coordination. Specialized cancer centers remain the destination for many patients, but the path to those centers is increasingly being managed by digital infrastructure designed to remove friction before treatment begins. The remaining challenge is not whether coordination matters; it is whether that coordination can be scaled without losing the speed, accuracy, and clinical judgment that oncology demands.